Table 4.
miRNAs involved in the pathogenesis of uterine leiomyosarcoma.
| MiRNAs | Biological Samples | Expression | Targets | Biological Events | Year Published | Refs. |
|---|---|---|---|---|---|---|
| let-7s | LMS tissues, SK-LMS-1, SK-UT-1, and SK-UT-1B cell lines | downregulated | HMGA2 | cell proliferation | 2008 | [228] |
| 72 miRNAs | LMS tissues | deregulated (32 up-Mir, 40 down-Mir) | NA | differentiation, neoplastic transformation | 2010 | [146] |
| miR-200c | SK-LMS-1 | downregulated | IKBKB, IL8, CDK2, and CCNE2 | inflammatory response, angiogenesis, cell cycle, migration | 2014 | [149] |
| miR-31 | metastatic and primary LMS tissues, SK-LMS-1 | downregulated in metastatic LMS tissues | MAPK signaling, Wnt signaling | metastasis | 2016 | [159] |
| miR-15a, miR- 92a | metastatic and primary LMS tissues | upregulated in metastatic LMS tissues | Wnt signaling | metastasis | 2016 | [159] |
| 13 miRNAs | LMS, MM, LMS-derived cell line | deregulated (8 up-Mir, 5 down-Mir) | BCL2, EGFR, VEGFA, IGF1R, EGF-R, MET, MYCN | tumor apoptosis, angiogenesis, proliferation | 2017 | [147] |
| miR-152 | LMS tissues, SK-LMS-1 |
downregulated | MET, KIT, PI3K/AKT (transcription factors) | cell proliferation, apoptosis, cell cycle | 2017 | [229] |
| miR-1 | LMS tissues | downregulated | NA | disrupted tumor suppression | 2018 | [154] |
| let-7 family | LMS tissues | downregulated | NA | PFS, OS | 2019 | [151] |
| miR-1246, miR-191-5p | serum from LMS patients | downregulated | NA | diagnostic biomarker | 2019 | [230] |
| miR-10b-5p | LMS tissues, SK-UT-1, SK-LMS-1 |
downregulated | G1/S checkpoint, MYC-mediated apoptosis, epithelial–mesenchymal transition | cell proliferation, cell cycle | 2023 | [145] |
| miR-130b | LMS, MM tissues, SK-LMS-1, SK-UT-1 | upregulated | TSC1 | tumor proliferation and metastasis | 2023 | [150] |
Note: LMS: leiomyosarcoma; MM: myometrium; NA: not available; PFS: progression-free survival; OS: overall survival.